AAP
BPMC

Ardsley Advisory Partners’s Blueprint Medicines BPMC Stock Holding History

Ardsley Advisory Partners’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-3,500
Closed -$273K – 151
2020
Q2 		$273K Buy
+3,500
New +$237K 0.06% 110
2020
Q1 		– Sell
-4,500
Closed -$360K – 115
2019
Q4 		$360K Buy
+4,500
New +$337K 0.06% 113

Other funds holding BPMC

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
CCM
Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Ardsley Advisory Partners's BPMC Position: Q3 2020 in Review

Ardsley Advisory Partners sold out of Blueprint Medicines (BPMC) in Q3 2020, closing a stake of 3,500 shares — an estimated $273K sold.

Ardsley Advisory Partners first reported a position in BPMC in Q4 2019 and held it in 2 quarters. The position peaked at $360K in Q4 2019. 236 funds tracked by Wall St. Rank hold BPMC as of Q3 2020.

  • Ardsley Advisory Partners reported no remaining Blueprint Medicines position as of Q3 2020 after selling out during the quarter.
  • Ardsley Advisory Partners sold 3,500 Blueprint Medicines shares in Q3 2020, an estimated $273K.
  • Ardsley Advisory Partners first reported a position in Blueprint Medicines in Q4 2019 and held it in 2 quarters.
  • Ardsley Advisory Partners's Blueprint Medicines position peaked at $360K in Q4 2019.
  • 236 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2020.

Based on Ardsley Advisory Partners's 13F filing for Q3 2020, filed 13 Nov 2020.